RxDoctor Payments Data

Kadirawelpillai Iswara, MD

Gastroenterology · Brooklyn, NYNPI 1265506828

Payments from drug & device makers

$147,874in general payments, 2019–2025

Across 870 payments — averaging $169.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$61K
  • AbbVie$48K
  • Pfizer$16K
  • Phathom Pharmaceuticals, Inc.$10K
  • Shionogi Inc$3K
  • Johnson & Johnson$1K
  • plus $7K from 33 others

What the payments were for

  • Consulting fees$6,7155%
  • Speaking & faculty fees$111,17075%
  • Travel & lodging$11,0827%
  • Food & beverage$18,78113%
  • Education$1250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$147,874 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$160,684
Medicare patients
399
Services billed
1,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase40$188,862
Dupixent SyringeDupilumab11$79,418
LinzessLinaclotide75$67,483
VoqueznaVonoprazan Fumarate70$58,517
IbsrelaTenapanor Hcl18$48,911
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate19$28,453
DexilantDexlansoprazole19$11,249
TrulancePlecanatide12$8,585
Mesalamine26$7,888
Dexlansoprazole DrDexlansoprazole27$6,331
Mesalamine ErMesalamine21$4,453
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates78$4,254
Pantoprazole Sodium370$4,154
ClenpiqSod Picosulf/Mag Ox/Citric Ac15$2,567
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl169$2,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$48,386$256,344115 claims
Phathom Pharmaceuticals, Inc.Voquezna$10,398$58,51770 claims
Ardelyx, Inc.Ibsrela$421$48,91118 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$638$11,24919 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,029$8,58512 claims
Ferring Pharmaceuticals Inc.Clenpiq$504$2,56715 claims
Braintree Laboratories, Inc.Sutab$608$1,94612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →